Evan Kearns Net Worth

Evan Kearns biography

Evan Kearns J.D. serves as Chief Compliance Officer, Vice President, General Counsel, Corporate Secretary of the Company. Mr. Kearns joined Agenus in 2014 as our Corporate Counsel and became our Associate General Counsel in 2015. Prior to Agenus, Mr. Kearns worked at the law firm Goodwin Procter LLP. Mr. Kearns holds a B.A. in Economics from Colby College and a J.D. degree from the University of Toledo College of Law.

What is the salary of Evan Kearns?

As the Chief Compliance Officer, Vice President, General Counsel, and Corporate Secretary of Agenus Inc, the total compensation of Evan Kearns at Agenus Inc is $1,610,580. There are 2 executives at Agenus Inc getting paid more, with Garo Armen having the highest compensation of $9,937,040.

How old is Evan Kearns?

Evan Kearns is 39, he's been the Chief Compliance Officer, Vice President, General Counsel, and Corporate Secretary of Agenus Inc since 2018. There are 13 older and no younger executives at Agenus Inc. The oldest executive at Agenus Inc is Wadih Jordan, 85, who is the Independent Director.

What's Evan Kearns's mailing address?

Evan's mailing address filed with the SEC is C/O AGENUS INC., 3 FORBES ROAK, LEXINGTON, MA, 02421.

Insiders trading at Agenus Inc

Over the last 23 years, insiders at Agenus Inc have traded over $24,466,328 worth of Agenus Inc stock and bought 13,248,226 units worth $63,837,873 . The most active insiders traders include Associates Gp Llcqvt Fund V..., Noubar Afeyan, and Corp Incyte. On average, Agenus Inc executives and independent directors trade stock every 99 days with the average trade being worth of $2,230,885. The most recent stock trade was executed by Garo H Armen on 15 February 2024, trading 500,000 units of AGEN stock currently worth $325,000.

What does Agenus Inc do?

agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody

Agenus Inc executives and stock owners

Agenus Inc executives and other stock owners filed with the SEC include:

• Garo Armen,
  Chairman of the Board, Chief Executive Officer, Co-Founder
• Jennifer Buell,
  President, Chief Operating Officer
• Evan Kearns,
  Chief Compliance Officer, Vice President, General Counsel, Corporate Secretary
• Dr. Garo H. Armen,
  Founder, Exec. Chairman & CEO
• Dr. Garo H. Armen Ph.D.,
  Founder, Exec. Chairman & CEO
• Brian Corvese,
  Independent Director
• Timothy Wright,
  Lead Independent Director
• Ulf Wiinberg,
  Independent Director
• Christine Klaskin,
  Chief Accounting Officer, Vice President - Finance
• Wadih Jordan,
  Independent Director
• Allison Jeynes-Ellis,
  Independent Director
• Christine M. Klaskin,
  VP of Fin., Principal Financial Officer & Principal Accounting Officer
• Susan Hirsch,
  Director
• Paul Clark,
  Director
• Donald Vidic,
  Vice President - Head of Commercial
• Dr. Steven J. O'Day M.D., Ph.D.,
  Chief Medical Officer
• Julie DeSander,
  Chief Bus. Officer
• Dr. Marcus Antonius van Dijk Ph.D.,
  Chief Technology Officer
• Alfred Dadson,
  Chief Manufacturing Officer
• Dhan Chand,
  Scientific Director & Head of Drug Discovery
• Paulo Moreira,
  Global Head of Clinical Operations
• John Castle,
  Head of Translational Medicine & Bioinformatics
• Adam Krauss J.D.,
  Chief Legal & Compliance Officer
• Regina Grebla Ph.D.,
  VP of Investor Relations & Communications
• Dr. Marc van Dijk Ph.D.,
  Chief Technology Officer
• Shahzad Malik,
  Director
• Jean Marie Cuillerot,
  Chief Medical Officer
• Corp Incyte,
  10% owner
• Charles Evan Ballantyne,
  CFO
• Robert Benjamin Stein,
  Chief Scientific Officer
• Shalini Sharp,
  Director
• Alex Duncan,
  Chief Technology Officer
• Eisen Margaret,
  Director
• Ozer Baysal,
  Chief Business Officer
• Associates Gp Llcqvt Fund V...,
  
• Tom Dechaene,
  Director
• Timothy G Rothwell,
  Director
• John Hatsopoulos,
  Director
• Hyam Levitsky,
  Director
• Kerry Wentworth,
  VP, Reg Affairs & Clinical Ops
• Karen Valentine,
  Chief Legal Officer
• Alastair Jj Wood,
  Director
• Pramod Srivastava,
  Director
• Roman Chicz,
  SVP Research & Preclinical Dev
• Bruce Leicher,
  VP, General Counsel
• Russell Herndon,
  Pres, Commercial Operations
• Gamil De Chadarevian,
  Director
• Mark Kessel,
  Director
• Peter J. Thornton,
  CFO & Sr. VP
• Frank V Iii Atlee,
  Director
• Noubar Afeyan,
  Director
• Jeff D Clark,
  Chief Financial Officer
• Renu Gupta,
  Sr. Vice President
• Neal Gordon,
  SrVP, Manufacturing Operations
• Christian Cortis,
  Chief Strategy Officer
• Thomas L Harrison,
  
• Adam Krauss,
  Chief Legal Officer
• Steven J O'day,
  Chief Medical Officer